Performance of the Orsiro Hybrid drug-eluting stent in high-risk subgroups.
Details
Serval ID
serval:BIB_85F7AA5D261C
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Performance of the Orsiro Hybrid drug-eluting stent in high-risk subgroups.
Journal
Minerva cardioangiologica
ISSN
1827-1618 (Electronic)
ISSN-L
0026-4725
Publication state
Published
Issued date
02/2016
Peer-reviewed
Oui
Volume
64
Number
1
Pages
55-73
Language
english
Notes
Publication types: Journal Article ; Research Support, Non-U.S. Gov't Publication Status: ppublish
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Publication types: Journal Article ; Research Support, Non-U.S. Gov't ; Review
Abstract
Newer-generation drug-eluting stents (DES) with enhanced biocompatibility that deliver antiproliferative drugs from a durable polymer have significantly improved safety and efficacy outcomes, compared with both early-generation DES and bare-metal stents, and they represent the current standard of care in all patient and lesion subsets. However, newer durable polymers have been associated with the occurrence of chronic inflammation, delayed vascular healing, incomplete endothelialisation, and neoatherosclerosis, which may result in persistent late adverse cardiovascular events, particularly in patients with high-risk baseline clinical features and angiographic complex coronary artery disease. Newer-generation DES with biodegradable polymer and controlled drug release have been recently introduced to overcome long-term adverse outcomes observed with both early-generation and newer-generation permanent polymer-based DES, and they may be of incremental clinical value in subgroups of patients at higher risk of stent failure. The recent ultrathin-strut cobalt-chromium Orsiro Hybrid DES (BIOTRONIK AG, Bülach, Switzerland) eluting sirolimus from a biodegradable polymer was designed to improve arterial healing and clinical outcomes. The Orsiro Hybrid DES has demonstrated clinical performance comparable to the current state-of-the-art newer-generation thin-strut cobalt-chromium, permanent polymer-based everolimus-eluting stent in a broad patient population. In subgroups of patients at highest-risk of adverse ischemic events, such as patients with diabetes mellitus, small vessels, long lesions, complex coronary lesions, multivessel disease, chronic total occlusion, or ST-segment elevation myocardial infarction, the Orsiro Hybrid DES has shown low rates of adverse clinical outcomes, similar to rates observed in lower-risk patients, and extremely low rates of definite stent thrombosis. This article reviews current evidence on safety and efficacy of the recent ultrathin-strut biodegradable polymer Orsiro Hybrid DES in high-risk subgroups.
Keywords
Chromium Alloys/chemistry, Coronary Artery Disease/therapy, Drug-Eluting Stents, Everolimus, Humans, Percutaneous Coronary Intervention/methods, Polymers/chemistry, Prosthesis Design, Risk Factors, Sirolimus/administration & dosage
Pubmed
Create date
11/10/2016 16:29
Last modification date
20/08/2019 15:45